Evidence for Somatostatin receptor 2 in thyroid tissue

• Published in: Regulatory peptides Vol. 138; no. 1; pp. 32 - 39
• Main Authors: Druckenthaner, M., Schwarzer, C., Ensinger, C., Gabriel, M., Prommegger, R., Riccabona, G., Decristoforo, C.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier B.V 10.01.2007; Amsterdam Elsevier
• Subjects: Actins - metabolism; Adult; Aged; Biological and medical sciences; Biomarkers - metabolism; Biomarkers, Tumor - metabolism; Female; Fundamental and applied biological sciences. Psychology; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) - metabolism; Humans; Immunohistochemistry; Male; Middle Aged; Receptor; Receptors, Somatostatin - genetics; Receptors, Somatostatin - metabolism; Reverse Transcriptase Polymerase Chain Reaction; Reverse-transcriptase PCR; RNA, Messenger - metabolism; Somatostatin; Thyroid; Thyroid Gland - metabolism; Thyroid Neoplasms - metabolism; Tumour; Vertebrates: endocrinology; Reverse-transcriptase PCR; Somatostatin; Tumour; Receptor; Thyroid; Endocrine gland; RNA-directed DNA polymerase; Somatostatin receptor; Enzyme; Transferases; Peptide hormone; Thyroid gland; Neuropeptide; Polymerase chain reaction; Nucleotidyltransferases; Tumor; Biological receptor
• ISSN: 0167-0115; 1873-1686
• DOI: 10.1016/j.regpep.2006.08.005

Somatostatin receptor scintigraphy has found considerable interest for imaging thyroid tumours. Recently, also therapeutic application of Somatostatin analogues labelled with beta-emitting radionuclides has been suggested as treatment option for thyroid tumours with absent radioiodine uptake. Most of the radiolabelled analogues available show a predominant affinity for Somatostatin receptor subtype 2. This study reports on the in vitro characterisation of Somatostatin receptor subtype mRNAs in thyroid tumours and normal thyroid tissue by means of RT-PCR. Surgical samples of 21 patients were collected, and mRNA of 16 tumour and 17 control specimen was isolated. mRNA expression for Somatostatin, SSTR subtype 1–5, thyroid markers (NIS, TSH, Tg, TPO) and control markers (GAPDH, β-actin) was determined. PCR results were correlated with immunohistochemistry staining using SSTR2 receptor specific antibodies. 94% of all samples expressed Somatostatin receptor mRNA with predominant expression of subtype 2, less predominant of subtype 5 and subtype 3. Somatostatin receptor subtype 2 mRNA expression correlated well with immunohistochemical staining pattern in 13/16 samples, SSTR2 immunohistochemistry was positive in 87% of the samples. Our results show that Somatostatin receptor 2 is predominantly expressed on thyroid tissue and is a valid target for treatment of thyroid tumours. Octreotide derivatives currently used in Nuclear medicine seem to be well suited to target receptors expressed in thyroid tumours.